Sunita Somvanshi
The U.S. Drug Enforcement Administration announced regulatory action on certain kratom products, and the internet has been flooded with headlines about kratom being banned. That’s not what’s happening. The action is more specific and still evolving, and understanding the actual status is important if you use kratom or know someone who does.
What the DEA did on August 26: it temporarily placed three synthetic derivatives of 7-hydroxymitragynine into Schedule I of the Controlled Substances Act. Those three substances are: mitragynine pseudoindoxyl, dihydro-7-hydroxymitragynine (also called MGM-15), and 9-fluoro-dihydro-7-hydroxymitragynine (also called MGM-16). The temporary scheduling is effective through August 26, 2028.
Separately, the DEA proposed temporary scheduling of concentrated 7-OH products above a specified threshold, but as of August 28, that threshold order had not yet been issued. The Federal Register shows that proposal was still under review with public comments being accepted.
Raw, natural kratom leaf remains unscheduled at the federal level. The regulatory action was not intended to target ordinary botanical kratom that does not exceed the proposed 7-OH threshold.
Here’s why this distinction matters: the DEA targeted specific compounds based on pharmacological data. Natural mitragynine, which is the primary alkaloid in raw kratom leaf, is a partial opioid agonist. The synthetic versions and highly concentrated 7-OH forms are full agonists—they bind to opioid receptors much more strongly. They carry greater abuse potential and greater respiratory depression risk. That pharmacological difference is what drove the DEA’s action on these specific compounds.
The American Kratom Association—the industry trade group—supported removing the manufactured synthetic versions while advocating for continued access to natural botanical kratom. They’re also pushing for standardized testing and age restrictions under something called the Kratom Consumer Protection Act. That’s a middle ground approach.
The regulatory process continues. Courts could challenge the scheduling. Public comment could influence the threshold determination. But right now, the emergency action places three synthetics into Schedule I. The threshold action for concentrated 7-OH remains pending.
What this means practically: most commercial kratom products sold at legal vendors are botanical—the raw leaf or basic extracts. The three compounds now banned are chemically synthesized versions that some vendors created specifically for high-potency effects. The threshold determination for concentrated 7-OH will clarify the next phase once it’s issued.
The regulatory landscape around kratom will continue evolving. The temporary scheduling allows the government time to determine whether these compounds should remain permanently controlled or whether the threat assessment changes.
